The American College of Rheumatology held its annual meeting in late 2025, and dozens of abstracts presented data from glucagon-like peptide-1 (GLP-1) receptor agonists research related to arthritis. (See page 2) These drugs, such as semaglutide and tirzepatide (Ozempic, Wegovy, Mounjaro), are best known as treatments for diabetes and weight loss, but studies are underway on arthritis in animals and humans. “Nearly every other patient in my clinic is on a GLP-1,” says Cleveland Clinic rheumatologist Stephanie Tancer, MD. But so far, Dr. Tancer is not the one prescribing the GLP-1s.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Arthritis Advisor
Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
